Checkpoint Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James F. Oliviero III,
- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 95 Sawyer Road Waltham MA United States of America 02453
- IPO Date
- Dec 19, 2016
- CIK
- 0001651407
- Website
- checkpointtx.com
- Similar Companies
- Business
- Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel antibody therapies for patients with solid tumor cancers, including advanced cutaneous squamous cell carcinoma, non-small cell lung cancer and other metastatic tumors. The company offers UNLOXCYT (cosibelimab-ipdl), the first FDA-approved PD-L1 blocking antibody indicated for advanced cutaneous squamous cell carcinoma received approval in December 2024; olafertinib (CK-301), a third-generation oral EGFR inhibitor in development for EGFR mutation-positive non-small cell lung cancer and other solid tumors; and earlier-stage candidates such as CK-302 (preclinical anti-PD-L1 antibody) and BET bromodomain inhibitors through partnerships. Checkpoint Therapeutics maintains licensing and collaboration agreements with Adimab LLC for cosibelimab development, NeuPharma Inc. for olafertinib commercialization, Jubilant Biosys Limited for BET inhibitors and Dana-Farber Cancer Institute for oncology research support. Founded in 2014 and headquartered in Waltham, Massachusetts, the company previously operated as a subsidiary of Fortress Biotech Inc. before its acquisition by Sun Pharmaceutical Industries Limited in May 2025 for $4.10 per share plus a contingent value right potentially worth up to $0.70 per share tied to cosibelimab regulatory approvals in Europe; this strategic transaction enhances global commercialization of UNLOXCYT leveraging Sun Pharma's infrastructure while providing Fortress with $28 million upfront, a 2.5% royalty on UNLOXCYT net sales and milestone payments up to $4.8 million. Checkpoint Therapeutics targets patients in the United States and internationally across oncology segments with a pipeline emphasizing immuno-oncology and precision-targeted therapies.
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
Checkpoint Therapeutics shares pop on acquisition by Sun Pharma
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
Sun Pharma to Acquire Checkpoint Therapeutics
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research